NCT01928940 is a Phase 2 clinical trial of dabrafenib in Solid Tumours, sponsored by GlaxoSmithKline.

Who is sponsoring NCT01928940?

NCT01928940 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT01928940?

Interventions in NCT01928940: dabrafenib, trametinib.

What condition does NCT01928940 study?

NCT01928940 studies Solid Tumours.

Is NCT01928940 still recruiting?

NCT01928940 is currently completed. Last updated 24 July 2017.

Are results published for NCT01928940?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-07-24 · How we verify

NCT01928940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Completed Phase 2 Results posted Last updated 24 July 2017

What this trial tests

Phase 2 trial testing dabrafenib in Solid Tumours in 12 participants. Completed in 4 July 2016.

Timeline

15 August 2013

Primary endpoint
18 September 2014

4 July 2016

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	15 August 2013
Primary completion	18 September 2014
Estimated completion	4 July 2016
Sites	2 locations across Japan

Drugs / interventions tested

dabrafenib (dabrafenib) — full drug profile →
trametinib (trametinib) — full drug profile →

Conditions studied

Solid Tumours — all drugs for Solid Tumours →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

20 and older, any sex, with Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Primary · From the start of study treatment until 30 days after study treatment discontinuation (average of 1.38 year)

An AE is defined as any untoward medical occurrence (MO) in a part. temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. SAE is defined as any untoward MO that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect and protocol-specific SAEs:ALT\>=3xup

Any AEs

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	6

Any SAEs

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Phase I: Number of Participants With a Dose-limiting Toxicity (DLT) Primary · From the start of study treatment until 21 days

A DLT was defined as an event occurred during the first 21 days after the first dose of study drugs and met any of the following criteria, according to National Cancer Institutes (NCI) common terminology criteria for AE (CTCAE) grade (G) version 4.0: G4 hematological toxicity; G3 or G4 non-hematologic toxicity (including rash, nausea, vomiting and diarrhea only if uncontrolled with supportive therapy); rash \>=G3 that required dose reduction despite supportive care; a G2 or greater non-hematological toxicity that in the judgment of the investigator and medical monitor; dose interruption of gre

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

Phase I: Number of Participants With the Indicated Worst-case Change From Baseline (BL) in the Indicated Clinical Chemistry Parameters (CCPs) Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

CCPs were graded according to NCI CTCAE grade version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters (para) for which an increase to G3 or G4 from BL G occurred. CCPs that were not G according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those para for which the category decreased to Low or increased to High relative to the BL category. The worst-case during the on-therapy period was determined taking into account both scheduled and un

Alkaline Phosphatase, G3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

ALT, G3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Inorganic Phosphorous, G4

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Chloride, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

LDH, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

LDH, High

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

Total Protein, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

Urea/BUN, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Phase I: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Hematology parameters were summarized according to NCI CTCAE G, version 4.0 as: G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 from Baseline G occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, were categorized as High and Low with respect to the normal range. Data are presented only for those parameters for which the category decreased to Low or increased to High relative to the Baseline category. The worst-case during the on-therapy period w

Lymphocytes, G3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Total Neutrophils, G3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Basophils, High

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Eosinophils, High

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Hematocrit, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

MCHC, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

MCH, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

MCV, Low

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Phase I: Number of Participants With the Indicated Urinalysis Parameters Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Urine samples were collected for urine dipstick analysis at Baseline and at the post-treatment Visit. The number of participants with negative (absence) and positive (presence: trace, 1+, 2+, 3+, 4+ or 5+) results for urine occult blood (UOB), urine glucose (UGLU), urine ketones (UKET), urine protein (UP) and urine urobilinogen (UUBIL) were summarized. The Baseline value is defined as the last pre-treatment value observed.

UOB, Baseline, Negative

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	6

UOB, Baseline, Positive

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

UOB, Post-Treatment, Negative

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

UOB, Post-Treatment, Positive

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

UGLU, Baseline, Negative

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	6

UGLU, Baseline, Positive

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

UGLU, Post-Treatment, Negative

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

UGLU, Post-Treatment, Positive

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

Phase I: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance (Pef) Status Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

The ECOG pef status 5-point scale is used to assess how a participant's disease is progressing, to assess how the disease affects the daily living abilities of the par. and to determine appropriate treatment and prognosis: G0, fully active, able to carry on all pre-disease pef without restriction. G1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, example, light house work, office work. G2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about \>50 percent (%) of waking hrs. G3, c

Improved

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

No change

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	4

Deteriorated

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Phase I: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3 Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were graded using (NCI CTCAE version 4.0). SBP was categorized as: G1 (Increase to \>=120 to 140 millimeters of mercury \[mmHg\]), G2 (Increase to \>=140 to \<160 mmHg), and G3 (Increase to \>=160 mmHg). DBP was categorized as: G1 (Increase to \>=80 to \<90 mmHg), G2 (Increase to \>=90 to \<100 mmHg), and G3 (Increase to \>=100 mmHg). The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments. An increase is defined as an increase in the CTCAE grade relative to

SBP, Increase to Grade 2

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

SBP, Increase to Grade 3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

DBP, Increase to Grade 2

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

DBP, Increase to Grade 3

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Change from Baseline in heart rate is categorized as decrease to \<60 beats per minute (bpm), change to normal or no change, and increase to \>100 bpm relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant's heart rate value decreased to \<60 bpm and increased to \>100 bpm post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

Decrease to <60 bpm

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Change to normal or no change

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

Increase to >100 bpm

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature Primary · From Baseline until the post-treatment Visit (average of 1.38 years)

Change from Baseline in temperature is categorized as a decrease to \<=35 degrees celsius (C), change to normal or no change as 35-38 degrees C, and increase to \>=38 degrees C relative to the Baseline value. Participants with a missing Baseline value are assumed to have a normal Baseline value. Participants were counted twice if the participant temperature value decreased to \<=35 degrees C and increased to \>=38 degrees C post-Baseline. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.

Decrease to <=35 degrees C

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

Change to normal or no change

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

Increase to >=38 degrees C

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	3

Phase I: Change From Baseline in Oxygen Saturation (SpO2) Measured Via Pulse Oxymetry at the Indicated Time Points Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Oxygen saturation measures the capacity of blood to transport oxygen to other parts of the body. Oxygen binds to hemoglobin in red blood cells when moving through the lungs. A pulse oximeter uses two frequencies of light (red and infrared) to determine the percentage of hemoglobin in the blood that is saturated with oxygen,that is called as blood oxygen saturation or SpO2. Change from Baseline was calculated as the individual post-Baseline value (Days 8,15; Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.

Day 8, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1.0	± 0.89

Day 15, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0.8	± 0.75

Week 3, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0.2	± 0.75

Week 8, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0.7	± 1.21

Week 12, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1.4	± 1.67

Week 16, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1.2	± 2.14

Week 20, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0.4	± 1.14

Week 24, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0.8	± 1.92

Phase I: Change From Baseline in Weight at the Indicated Time Points Primary · From Baseline until the post-treatment Visit ( average of 1.38 year)

Mean change in body weight from Baseline was determined. Change from Baseline was calculated as the individual post-Baseline value (Weeks 3 to 136 and post-treatment Visit) minus the Baseline value. The Baseline value is defined as the last pre-treatment value observed.

Week 3, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-4.87	± 6.046

Week 8, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-4.43	± 6.274

Week 12, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-4.13	± 6.436

Week 16, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-4.00	± 6.801

Week 20, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-0.62	± 2.295

Week 24, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-0.70	± 1.402

Week 28, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-0.36	± 1.850

Week 32, n=5

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	-0.38	± 1.809

Phase I: Number of Participants With the Indicated Electrocardiogram (ECG) Findings at the Indicated Time Points Primary · From Baseline until the post-treatment Visit (average of 1.38 year)

Single twelve (12)-lead ECGs were perfomred at Baseline, Weeks 3 to 132 and post-treatment Visit. ECG findings were categorized as: normal, abnormal - clinically significant (CS), or abnormal - not clinically significant (NCS), as determined by the investigator.

Baseline, Normal, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	4

Baseline, Abnormal-NCS, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	2

Baseline, Abnormal-CS, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

Week 3, Normal, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	5

Week 3, Abnormal-NCS, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Week 3, Abnormal-CS, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	0

Week 12, Normal, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	5

Week 12, Abnormal-NCS, n=6

Group	Value	95% CI
Phase I: GSK2118436 150 mg + GSK1120212 2 mg	1

Adverse events — posted to ClinicalTrials.gov

Time frame: On treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of investigational product (IP) until 30 days after the last dose of IP (average of 1.38 years).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase I: GSK2118436 150 mg + GSK1120212 2 mg

Serious: 1/6 (17%)

Deaths: —

Phase II: GSK2118436 150 mg + GSK1120212 2 mg

Serious: 0/6 (0%)

Deaths: —

Serious adverse events (1 terms)

Reaction	System	Phase I: GSK2118436 150 mg…	Phase II: GSK2118436 150 m…
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—

Other adverse events (81 terms — click to expand)

Reaction	System	Phase I: GSK2118436 150 mg…	Phase II: GSK2118436 150 m…
Pyrexia	General disorders	—	—
Oedema peripheral	General disorders	—	—
Aspartate aminotransferase increased	Investigations	—	—
Erythema	Skin and subcutaneous tissue disorders	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—
Nasopharyngitis	Infections and infestations	—	—
Blood alkaline phosphatase increased	Investigations	—	—
Stomatitis	Gastrointestinal disorders	—	—
Dermatitis acneiform	Skin and subcutaneous tissue disorders	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—
Headache	Nervous system disorders	—	—
Neutropenia	Blood and lymphatic system disorders	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—
Alanine aminotransferase increased	Investigations	—	—
Neutrophil count decreased	Investigations	—	—
Constipation	Gastrointestinal disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—
Rash	Skin and subcutaneous tissue disorders	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—
Chills	General disorders	—	—
Malaise	General disorders	—	—
Fatigue	General disorders	—	—
Oedema	General disorders	—	—
Pain	General disorders	—	—
Blood glucose increased	Investigations	—	—
Blood phosphorus decreased	Investigations	—	—
Blood albumin decreased	Investigations	—	—
Blood lactate dehydrogenase increased	Investigations	—	—
Blood pressure increased	Investigations	—	—
Ejection fraction decreased	Investigations	—	—
Electrocardiogram QT prolonged	Investigations	—	—
Eosinophil count increased	Investigations	—	—
Glucose urine present	Investigations	—	—
Haemoglobin decreased	Investigations	—	—
Platelet count decreased	Investigations	—	—
Weight increased	Investigations	—	—

Most-reported serious reactions: Pneumonitis.

Data from ClinicalTrials.gov NCT01928940 adverse events section.

Sponsor's own description

This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

The MAPK pathway across different malignancies: a new perspective.
Burotto M, Chiou VL, Lee JM, Kohn EC. · · 2014 · cited 773× · PMID 24948110 · DOI 10.1002/cncr.28864
No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR, Saturno G, Lorigan P, Marais R. · · 2014 · cited 37× · PMID 25178978 · DOI 10.1016/j.molonc.2014.07.027
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
Luke JJ, Ott PA. · · 2014 · cited 25× · PMID 25018652 · DOI 10.2147/dhps.s39568
The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies.
Imani S, Roozitalab G, Emadi M, Moradi A, et al · · 2024 · cited 23× · PMID 39582535 · DOI 10.3389/fonc.2024.1504142
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, et al · · 2018 · cited 17× · PMID 29399853 · DOI 10.1111/1346-8138.14210
Targeted Therapies in Melanoma: Translational Research at Its Finest.
Ho AW, Tsao H. · · 2015 · cited 9× · PMID 26174532 · DOI 10.1038/jid.2015.14

Verify or expand the search:

Other trials of dabrafenib

Trials testing the same drug.

NCT04961619 — Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. · completed
NCT05299580 — "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II · Phase 2 · withdrawn
NCT04666272 — Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With St · active not recruiting
NCT03975829 — Pediatric Long-Term Follow-up and Rollover Study · Phase 4 · active not recruiting
NCT03553329 — Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti B · completed

Other recruiting trials for Solid Tumours

Currently open trials in the same condition.

NCT07391670 — A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval · Phase 1 · recruiting
NCT07446855 — Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homo · Phase 1, PHASE2 · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07165067 — A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01928940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 24 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01928940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing